![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Corrected Proof)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
| Item Type: | Review |
|---|---|
| Title: | What is cardiometabolic HFpEF and how can we study it preclinically? |
| Creators Name: | Daou, Daniel, Tong, Dan, Schiattarella, Gabriele G., Gillette, Thomas G. and Hill, Joseph A. |
| Abstract: | Cardiometabolic heart failure with preserved ejection fraction (HFpEF) has emerged as a distinct and dominant endotype of HFpEF. Driven by prevalent comorbidities, its incidence and prevalence are projected to continue to rise amid the current global pandemic of obesity and metabolic disease. Recognizing the characteristic clinical and molecular features of cardiometabolic HFpEF is paramount for developing an efficacious therapeutic arsenal and improving clinical outcomes, challenges in which success to date has been modest. Studying relevant and clinically informative animal models of cardiometabolic HFpEF can afford valuable insights into the molecular underpinnings of this syndrome, allowing the possibility of novel advances with clinical relevance. Here, we outline the clinical and molecular features that define cardiometabolic HFpEF as a distinct endotype. We also discuss the bona fide animal models of cardiometabolic HFpEF currently available, as well as methods for developing new models. |
| Keywords: | Cardiometabolic, Heart Failure with Preserved Ejection Fraction, Preclinical Models, Animals, Mice |
| Source: | JACC: Basic to Translational Science |
| ISSN: | 2452-302X |
| Publisher: | Elsevier / American College of Cardiology |
| Page Range: | 101295 |
| Date: | 30 July 2025 |
| Official Publication: | https://doi.org/10.1016/j.jacbts.2025.04.009 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
